Term ends Mar 30, 2028 · High confidence
20-year base term ends Mar 12, 2028
Held by GlaxoSmithKline LLC
Filed Apr 20, 2022 as application 17/724,825 · Granted Mar 10, 2026
Base term plus 276 days of patent term adjustment (USPTO delay) · capped by a resolved terminal disclaimer
Today
2008
2028
Clock starts
Mar 12, 2008
Mar 12, 2008
Term ends
Mar 30, 2028
Mar 30, 2028
Granted
Mar 10, 2026
Mar 10, 2026
base term
patent term adjustment
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
276
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
Capped
Terminal disclaimer
Resolved from the filed document, referencing US 9,233,934, US 9,238,628.
None due
Maintenance fees
This term ends before the first maintenance fee's grace period does, 4 years from grant, so no fee can end it early.
7
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 276 days past its 20-year base term on prosecution delay. A terminal disclaimer resolved from the filed document caps it earlier. No maintenance fee can end this term early. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Mar 12, 2008, when application PCT/AU2008/000339, the earliest non-provisional in its chain, was filed (this one was filed Apr 20, 2022) | Mar 12, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +276 days, USPTO patent term adjustment record | Dec 13, 2028 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 9,233,934, US 9,238,628) | capped to Mar 30, 2028 | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No maintenance fee can end the term early | In force | High confidence |
| Computed term end | The steps above, in order | Mar 30, 2028 | High confidence |
This family
| US 8,486,941 | In force Jan 2035 | Jan 2035 |
| US 9,238,628 | In force Mar 2028 | Mar 2028 |
| US 9,233,934 | In force Jun 2028 | Jun 2028 |
| Application 14/960,710 | Abandoned not computed | not computed |
| US 12,570,614 | this patent Mar 2028 | Mar 2028 |
| Application 19/459,164 | Pending not computed | not computed |
6 of 7 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| May 26, 2023 Reel 63777, frame 344 | Burns, Christopher John; Donohue, Andrew Craig; Feutrill, John Thomas; Wilks, Andrew Frederick; Zeng, Jun; Nguyen, Thao Lien Thi | Cytopia Research Pty Ltd. | Assignment of Assignor's Interest |
| May 26, 2023 Reel 63777, frame 396 | Ym Biosciences Australia Pty Ltd. | Sierra Oncology, Inc. | Assignment of Assignor's Interest |
| May 26, 2023 Reel 63790, frame 568 | Sierra Oncology, Inc. | Sierra Oncology LLC | Change of Name |
| May 26, 2023 Reel 64146, frame 986 | Cytopia Research Pty Ltd. | Ym Biosciences Australia Pty Ltd. | Change of Name |
| Jun 7, 2023 Reel 63879, frame 821 | Sierra Oncology LLC | GlaxoSmithKline LLC | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2028
Term ends Mar 30, 2028. No further fees fall due before then
Note
The 276 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Disclaimer cap
This term is capped by a terminal disclaimer resolved from the filed document, referencing US 9,233,934, US 9,238,628.
Citations
We have no citation count for this patent yet. That is not the same as never having been cited.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.